Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,663 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01116128 | Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients(D-MP) | terminated | Phase 2 | 8 | Fondazione EMN Italy OnlusOTHER | 1 | Jun 14, 2011 | clinicaltrials |
| NCT00344422 | Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 198 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY |
| 0 |
| Jun 10, 2011 |
| clinicaltrials |
| NCT01010880 | Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 16 | Biokine Therapeutics LtdINDUSTRY | 1 | Jun 10, 2011 | clinicaltrials |
| NCT01370434 | Two Cycles of PAD Combination by AHCT in MM(PADinMM) | completed | Phase 2 | 43 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00270101 | The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | completed | Phase 3 | 156 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00270166 | The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy | completed | Phase 3 | 201 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00216697 | An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy | completed | Phase 2 | 13 | Janssen Pharmaceutical K.K.INDUSTRY | 0 | May 17, 2011 | clinicaltrials |
| NCT00752518 | A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 35 | Janssen Pharmaceutical K.K.INDUSTRY | 0 | May 17, 2011 | clinicaltrials |
| NCT00621400 | Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis | completed | Phase 1 / Phase 2 | 27 | Nantes University HospitalOTHER | 1 | May 10, 2011 | clinicaltrials |
| NCT00193518 | Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 41 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00577668 | A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00216151 | Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma | terminated | Phase 2 | 3 | Hoosier Cancer Research NetworkOTHER | 1 | May 2, 2011 | clinicaltrials |
| NCT01341262 | THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM) | completed | Phase 2 | 378 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 0 | Apr 25, 2011 | clinicaltrials |
| NCT01322776 | Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Mar 25, 2011 | clinicaltrials |
| NCT01296204 | Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131(BB4) | completed | Phase 1 | 33 | Centre René GauducheauOTHER | 1 | Mar 22, 2011 | clinicaltrials |
| NCT01170052 | Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) | withdrawn | Phase 1 / Phase 2 | 20 | Charite University, Berlin, GermanyOTHER | 1 | Mar 16, 2011 | clinicaltrials |
| NCT00290095 | Quality of Life in Patients With Multiple Myeloma | completed | — | 260 | Ullevaal University HospitalOTHER | 1 | Mar 8, 2011 | clinicaltrials |
| NCT00481858 | Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis(CRC011) | completed | — | 150 | KineMedINDUSTRY | 1 | Feb 28, 2011 | clinicaltrials |
| NCT00772811 | Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma(Flu-Mel) | completed | Phase 2 | 38 | Cooperative Study Group A for HematologyNETWORK | 1 | Feb 17, 2011 | clinicaltrials |
| NCT00499018 | Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma(DLCL04) | unknown | Phase 3 | 399 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 15, 2011 | clinicaltrials |
| NCT00774826 | Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma | unknown | Phase 3 | 534 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 15, 2011 | clinicaltrials |
| NCT01296503 | Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma | completed | Phase 3 | 213 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Feb 15, 2011 | clinicaltrials |
| NCT00185653 | Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma | completed | N/A | 40 | Stanford UniversityOTHER | 1 | Feb 14, 2011 | clinicaltrials |
| NCT00602511 | Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma | completed | Phase 3 | 300 | Nordic Myeloma Study GroupOTHER | 3 | Feb 9, 2011 | clinicaltrials |
| NCT00285103 | SPC2996 in Chronic Lymphocytic Leukaemia | completed | Phase 1 / Phase 2 | 46 | Santaris Pharma A/SINDUSTRY | 4 | Feb 2, 2011 | clinicaltrials |
| NCT00050687 | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | terminated | Phase 1 / Phase 2 | — | Titan PharmaceuticalsINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT01277172 | TREatment of degeNerative and Neoplastic Diseases With Rituximab(TREND) | unknown | Phase 2 / Phase 3 | 54 | Probiomed S.A. de C.V.INDUSTRY | 1 | Jan 14, 2011 | clinicaltrials |
| NCT00388635 | Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. | completed | Phase 1 / Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | Jan 11, 2011 | clinicaltrials |
| NCT01274403 | A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma | completed | Phase 2 | 130 | Gruppo Italiano Studio LinfomiOTHER | 1 | Jan 11, 2011 | clinicaltrials |
| NCT01021358 | A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax). | completed | Phase 1 | 12 | AbbottINDUSTRY | 1 | Dec 20, 2010 | clinicaltrials |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Dec 9, 2010 | clinicaltrials |
| NCT01250808 | Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy | available | — | — | Peking UniversityOTHER | 1 | Dec 1, 2010 | clinicaltrials |
| NCT01249690 | Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma | unknown | Phase 4 | 100 | Second Military Medical UniversityOTHER | 1 | Nov 30, 2010 | clinicaltrials |
| NCT00386321 | Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma | terminated | Phase 2 | 10 | Chulalongkorn UniversityOTHER | 1 | Nov 18, 2010 | clinicaltrials |
| NCT00162500 | A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies | withdrawn | Phase 2 | 15 | Hadassah Medical OrganizationOTHER | 1 | Nov 10, 2010 | clinicaltrials |
| NCT01234129 | Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma | completed | — | 320 | Instituto Mexicano del Seguro SocialOTHER_GOV | 1 | Nov 4, 2010 | clinicaltrials |
| NCT01233895 | Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma | completed | Phase 1 | 26 | SanofiINDUSTRY | 2 | Nov 3, 2010 | clinicaltrials |
| NCT00935597 | Host Dendritic Cells in Allograft Patients | unknown | Phase 1 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 29, 2010 | clinicaltrials |
| NCT00136591 | A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma | terminated | Phase 2 | 87 | Lymphoma Study AssociationOTHER | 2 | Oct 26, 2010 | clinicaltrials |
| NCT00095680 | Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma | completed | Phase 2 | 30 | Scios, Inc.INDUSTRY | 0 | Oct 22, 2010 | clinicaltrials |
| NCT00689000 | Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 57 | Chroma TherapeuticsINDUSTRY | 1 | Oct 22, 2010 | clinicaltrials |
| NCT00087867 | Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma | completed | Phase 2 | 62 | Scios, Inc.INDUSTRY | 0 | Oct 18, 2010 | clinicaltrials |
| NCT00743028 | Assess the Oral Bioavailability of New ABT-263 Formulations | completed | Phase 1 | 36 | AbbottINDUSTRY | 1 | Oct 7, 2010 | clinicaltrials |
| NCT00923663 | Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type | unknown | Phase 2 | 16 | Medical University of ViennaOTHER | 1 | Sep 28, 2010 | clinicaltrials |
| NCT00186238 | High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma | completed | Phase 2 | 300 | Stanford UniversityOTHER | 1 | Sep 14, 2010 | clinicaltrials |
| NCT00892827 | Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia | unknown | Phase 2 | 10 | Wolfson Medical CenterOTHER_GOV | 1 | Sep 14, 2010 | clinicaltrials |
| NCT00628238 | Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | unknown | Phase 2 | 80 | Chronic Lymphocytic Leukemia Research ConsortiumNETWORK | 1 | Sep 10, 2010 | clinicaltrials |
| NCT00440388 | Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 23 | Ascenta TherapeuticsINDUSTRY | 1 | Aug 27, 2010 | clinicaltrials |
| NCT00286780 | Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 19 | Ascenta TherapeuticsINDUSTRY | 1 | Aug 13, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Jun 14, 2011source: clinicaltrials